Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab versus investigator's choice treatment in advanced gastric adenocarcinoma with peritoneal metastases
CTR20201246Phase 3Active
- Sponsor
- Linton Pacific
- Start
- Apr 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of catumaxomab in gastric adenocarcinoma, sponsored by Linton Pacific. Started Apr 2021; status: active.
02
Drugs
catumaxomab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on CTR20201246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201246.